Title
A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)Study map
Overview / Summary
Study details
Participating countries are:
Germany (Prof. Katja Weisel from Hamburg as study PI and country coordinator) – active
Italy (Prof. Antonietta Falcone from San Giovanni Rotondo as country coordinator) – active
Greece (Prof. Evangelos Terpos from Athens as country coordinator) – active
France (Prof. Philippe Moreau from Nantes as country coordinator)
Netherland (Prof. Ruth Wester from Rotterdam as country coordinator) – active
Spain (Prof. Paula Rodriguez Otero from Pamplona as country coordinator) – active
United States – active
Patient eligibility criteria
Pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an IMiD, PI and an anti-CD38 mAb.
Publications
No publications connected to this trial at the moment
